Rectal Adenocarcinoma — Trials

Rectal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 28
Ph III recruiting: 3
Growth YoY: —
Industry share: 2%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–9 of 9 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06625515	First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers	terminated	Phase 1	17	Accent TherapeuticsINDUSTRY	1	Feb 24, 2026	clinicaltrials
NCT04406857	Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer	terminated	Phase 1	1	National Cancer Institute (NCI)NIH	1	Feb 26, 2025